Jump to ContentJump to Main Navigation
Show Summary Details
More options …

Journal of Perinatal Medicine

Official Journal of the World Association of Perinatal Medicine

Editor-in-Chief: Dudenhausen, MD, FRCOG, Joachim W.

Ed. by Bancalari, Eduardo / Chappelle, Joseph / Chervenak, Frank A. / D'Addario , Vincenzo / Genc, Mehmet R. / Greenough, Anne / Grunebaum, Amos / Konje, Justin C. / Kurjak M.D., Asim / Romero, Roberto / Zalud, MD PhD, Ivica


IMPACT FACTOR 2018: 1.361
5-year IMPACT FACTOR: 1.578

CiteScore 2018: 1.29

SCImago Journal Rank (SJR) 2018: 0.522
Source Normalized Impact per Paper (SNIP) 2018: 0.602

Online
ISSN
1619-3997
See all formats and pricing
More options …
Volume 47, Issue 7

Issues

The predictive value of serum cancer antigen 125 (CA125) levels on pregnancy outcome in threatened miscarriages

Mosunmola A. Adeku / Omololu Adegbola / Godwin O. Ajayi
  • Prenatal Diagnosis and Therapy Centre, Department of Obstetrics and Gynaecology, College of Medicine, University of Lagos, Lagos State, Nigeria
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
Published Online: 2019-08-17 | DOI: https://doi.org/10.1515/jpm-2019-0097

Abstract

Background

Spontaneous miscarriages are common pregnancy complications which result in psychological and emotional burden in the affected women. It is therefore necessary to identify biomarkers that can predict pregnancy outcome in women with threatened miscarriages so as to assist in their counselling and management.

Methods

The study compared levels of maternal serum CA125 in 65 pregnancies with threatened miscarriages (study group) with 65 normal intrauterine pregnancies (control group) between 6 weeks and 19 weeks + 6 days gestation using an enzyme linked immunosorbent assay (ELISA) technique.

Results

The mean age of the study and control groups were 29.5 ± 0.14 years and 30.1 ± 0.14 years, respectively. The mean serum CA125 in the study group was 30.1 ± 1.1 IU/mL while that of the control group was 22.9 ± 1.2 IU/mL and this was statistically significant (P = 0.0001). The mean serum CA125 level in the women whose pregnancies were aborted (aborters) was 34.8 ± 1.4 IU/mL while the mean value among those whose pregnancies continued till term (non-aborters) was 27.3 ± 1.2 IU/mL. This was statistically significant (P = 0.001). Further analysis using CA125 ≥36.2 IU/mL (mean value of serum CA125 among aborters + 1 standard deviation) as a threshold for intrauterine pregnancies that eventually got aborted showed a sensitivity of 66.7%, specificity of 83.3%, positive predictive value of 55.6%, negative predictive value of 88.9% and the diagnostic effectiveness (accuracy) was 79.4%.

Conclusion

The measurement of serum CA125 is a useful predictor of pregnancy outcome in threatened miscarriages.

Keywords: normal pregnancy; serum CA 125; threatened miscarriage

References

  • 1.

    Lathi RB, Gray Hazard FK, Heerema-McKenney A, Taylor J, Chueh JT. First trimester miscarriage evaluation. Semin Reprod Med 2011;29:463–9.CrossrefPubMedWeb of ScienceGoogle Scholar

  • 2.

    Morhee R, Morhee E. Overview of the law and the availability of abortion services in Ghana. Ghana Med J 2006;40:80–6.PubMedGoogle Scholar

  • 3.

    Gracia CR, Samuel MD, Chittams J, Hummel AC, Shaunik A, Barnhart KT. Risk factor for spontaneous abortion in early symptomatic first-trimester pregnancies. Obstet Gynecol 2005;106:993–9.PubMedCrossrefGoogle Scholar

  • 4.

    Adegbola O, Akindele MO. The pattern and challenges of infertility management in Lagos, Nigeria. Afr Health Sci 2013;13:1126–9.PubMedGoogle Scholar

  • 5.

    Zinaman MJ, Clegg ED, Brown CC, O’Connor J, Selevan SG. Estimates of human fertility and pregnancy loss. Fertil Steril 1996;65:503–9.PubMedGoogle Scholar

  • 6.

    Ellish NJ, Saboda K, O’Connor J, Nasca PC, Stanek EJ, Boyle C. A prospective study of early pregnancy loss. Hum Reprod 1996;11:406–12.CrossrefPubMedGoogle Scholar

  • 7.

    Jouppila P, Huhtaniemi J, Tapanainen J. Early pregnancy failure: study by ultrasonic and hormonal methods. Obstet Gynecol 1980;55:42–7.PubMedGoogle Scholar

  • 8.

    Bast Jr RC, Feeney M, Lazarus H, Nadler LM, Colvin RB, Knapp RC. Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest 1981;68:1331–7.CrossrefPubMedGoogle Scholar

  • 9.

    Yin BW, Lloyd KO. Molecular cloning of the CA125 ovarian cancer antigen: identification as a new mucin, MUC16. J Biol Chem 2001;276:27371–5.CrossrefPubMedGoogle Scholar

  • 10.

    Osman N, O’ Leary N, Mulcahy E, Barrett N, Wallis F, Hickey K, et al. Correlation of serum CA125 with stage, grade and survival of patients with epithelial ovarian cancer at a single centre. Ir Med J 2008;101:245–7.Google Scholar

  • 11.

    Bast RC Jr, Xu FJ, Yu YH, Barnhill S, Zhang Z, Mills GB. CA125: the past and the future. Int J Biol Markers 1998;13:179–87.CrossrefPubMedGoogle Scholar

  • 12.

    Bagan P, Berna P, Assouad J, Hupertan V, Le Pimpec Barthes F, Riquet M. Value of cancer antigen 125 for diagnosis of pleural endometriosis in females with recurrent pneumothorax. Eur Respir J 2008;31:140–2.Web of ScienceCrossrefPubMedGoogle Scholar

  • 13.

    Sarandakou A, Protonotariou E, Rizos D. Tumor markers in biological fluids associated with pregnancy. Crit Rev Clin Lab Sci 2007;44:151–78.Web of SciencePubMedCrossrefGoogle Scholar

  • 14.

    Fiegler P, Kaminski P, Wegrzyn P. Serum CA125 variability – new aspects of clinical usefulness. Ginekol Pol 2003;74:412–8.PubMedGoogle Scholar

  • 15.

    Seki K, Kikuchi Y, Uesato T, Kato K. Increased serum CA125 levels during the first trimester of pregnancy. Acta Obstet Gynecol Scand 1986;65:583–5.PubMedCrossrefGoogle Scholar

  • 16.

    Quirk Jr JG, Brunson GL, Long CA, Bannon GA, Sanders MM, O’Brien TJ. CA 125 in tissues and amniotic fluid during pregnancy. Am J Obstet Gynecol 1988;159:644–9.CrossrefPubMedGoogle Scholar

  • 17.

    Han SN, Lotgerink A, Gziri MM, Van Calsteren K, Hanssens M, Amant F. Physiologic variables of serum tumor markers in gynecological malignancies during pregnancy: a systematic review. BMC Med 2012;10:86.CrossrefGoogle Scholar

  • 18.

    O’ Brien TJ, Hardin JW, Bannon GA, Norris JS, Quirk G Jr. CA125 antigen in human amniotic fluid and fetal membrane. Am J Obstet Gynecol 1986;155:50–5.CrossrefPubMedGoogle Scholar

  • 19.

    Ayaty S, Roudsari FV, Tavassoly F. CA125 in normal pregnancy and threatened abortion. Iran J Reprod Med 2007;5:57–60.Google Scholar

  • 20.

    Spitzer M, Kaushal N, Benjamin F. Maternal CA125 levels in pregnancy and the puerperium. J Reprod Med 1998;43:387–92.PubMedGoogle Scholar

  • 21.

    Scarpellini F, Mastrone M, Sbrasia M, Scarpellini L. Serum CA125 and first trimester abortion. Int J Gynaecol Obstet 1995;49:259–64.PubMedCrossrefGoogle Scholar

  • 22.

    Schmidt T, Rein DT, Foth D, Eibach HW, Kurbacher CM, Mallman P, et al. Prognostic value of repeated serum CA125 measurements in first trimester of pregnancy. Eur J Obstet Gynecol Reprod Biol 2001;97:168–73.CrossrefPubMedGoogle Scholar

  • 23.

    Fiegler P, Katz M, Kaminski K, Radol G. Clinical value of a single CA-125 level in women with symptoms of imminent abortion during the first trimester of pregnancy. J Reprod Med 2003;48:982–8.PubMedGoogle Scholar

  • 24.

    Ocer F, Bese T, Saridogan E, Aydinli K, Atastu T. The prognostic significance of maternal serum CA125 measurement in threatened abortion. Eur J Obstet Gynecol 1992;46:137–42.CrossrefGoogle Scholar

  • 25.

    Azogui G, Yaronovski A, Zohar S, Ben-Shiomo I. CA-125 is elevated in viable pregnancies destined to be miscarried: a prospective longitudinal study. Fert Steril 1996;65:1059–61.CrossrefGoogle Scholar

  • 26.

    Hornstein MD, Check JH, Hill JA. Serum CA125 levels and spontaneous abortion. Am J Obstet Gynecol 1995;172:695–9.CrossrefPubMedGoogle Scholar

  • 27.

    Mahdi BM. Estimation of CA-125 level in first trimester threatened abortion. Internet J Gynecol Obstet 2010;12:1–5.Google Scholar

  • 28.

    Vavilis D, Loufopoulos A, Karavida A, Zournatzi V, Tzitzimikas S, Dinas C, et al. Serum maternal carcinoembryonic antigen-125 (CA125) antigen levels in first trimester threatened abortion with demonstrable fetal heart activity. Middle East Fertil Soc J 2001;6:159–62.Google Scholar

  • 29.

    Katsikis I, Rousso D, Piouka A, Farmakiotis D, Kourtis A, Koiou-Zournatzi V, et al. Diagnostic value of progesterone and CA125 in the prediction of ectopic and abortive intrauterine gestations. Hippokratia 2005;9:124–9.Google Scholar

  • 30.

    Prabhakara GN. Biostatistics. 1st ed. New Delhi: Jaypee Brothers Medical Publishers Ltd; 2006.Google Scholar

  • 31.

    Katsikis I, Rousso D, Farmakiotis D, Kourtis A, Diamanti-Kandarakis E, Panidis D. Receiver operator characteristics and diagnostic value of progesterone and CA-125 in the prediction of ectopic pregnancy and abortive intrauterine gestations. Eur J Obstet Gynecol Reprod Biol 2006;125:226–32.PubMedCrossrefGoogle Scholar

About the article

Corresponding author: Dr. Omololu Adegbola, MBBS, FWACS, FMCOG, Department of Obstetrics and Gynaecology, College of Medicine, University of Lagos/Lagos University Teaching Hospital, P.M.B. 12003, Lagos, Nigeria, Tel.: +(234) 802-322-5033


Received: 2019-03-20

Accepted: 2019-06-21

Published Online: 2019-08-17

Published in Print: 2019-09-25


Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.

Research funding: None declared.

Employment or leadership: None declared.

Honorarium: None declared.

Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.


Citation Information: Journal of Perinatal Medicine, Volume 47, Issue 7, Pages 704–709, ISSN (Online) 1619-3997, ISSN (Print) 0300-5577, DOI: https://doi.org/10.1515/jpm-2019-0097.

Export Citation

©2019 Walter de Gruyter GmbH, Berlin/Boston.Get Permission

Comments (0)

Please log in or register to comment.
Log in